Introduction
Prostate cancer is the most common cancer in men. Although selective radiation, surgery and hormone ablation therapy have greatly improved the detection and treatment of early stage prostate cancer, few options exist to treat metastatic, castrate-resistant prostate cancer (CRPC). We have developed a therapeutic approach that uses a bispecific SCORPION™ (multi-specific protein therapeutics) molecule that redirects T cell cytotoxicity against cells expressing a common prostate cancer antigen, PSMA (Prostatic Specific Membrane Antigen).

Targeting PSMA

SCORPION molecules are bispecific antibody-like therapeutics containing two sets of binding domains linked to immunoglobulin Fc domains to extend the SCORPION molecules to be bispecific antibody-like therapeutics containing two sets of binding domains linked to immunoglobulin Fc domains to extend the

SCORPION molecules are bispecific antibody-like therapeutics containing two sets of binding domains linked to immunoglobulin Fc domains to extend the

SCORPION proteins were stable after freeze/thaw in mouse serum and performed a cytotoxicity assay as described above.

SCORPION Proteomics

SCORPION molecules are bispecific antibody-like therapeutics containing two sets of binding domains linked to immunoglobulin Fc domains to extend the SCORPION molecules to be bispecific antibody-like therapeutics containing two sets of binding domains linked to immunoglobulin Fc domains to extend the SCORPION molecules to be bispecific antibody-like therapeutics containing two sets of binding domains linked to immunoglobulin Fc domains to extend the SCORPION molecules to be bispecific antibody-like therapeutics containing two sets of binding domains linked to immunoglobulin Fc domains to extend the SCORPION molecules to be bispecific antibody-like therapeutics containing two sets of binding domains linked to immunoglobulin Fc domains to extend the SCORPION molecules to be bispecific antibody-like therapeutics containing two sets of binding domains linked to immunoglobulin Fc domains to extend the SCORPION molecules to be bispecific antibody-like therapeutics containing two sets of binding domains linked to immunoglobulin Fc domains to extend the SCORPION molecules to be bispecific antibody-like therapeutics containing two sets of binding domains linked to immunoglobulin Fc domains to extend the

SCORPION™ and any and all Emergent BioSolutions, Inc. brand, product, service and feature names or logos mentioned herein are trademarks of Emergent BioSolutions, Inc. or its subsidiaries in the United States or other countries. All rights reserved.

References